Ian Churcher, VP Drug Discovery, authors an article in The PharmaLetter this month looking at the challenges facing drug discovery. In it, Ian discusses the approaching disruption from technology companies and the shift the pharma must embrace to ensure that the industry can maintain its position as leaders in drug discovery.
BenevolentAI and Action Against AMD, a group of UK sight loss charities, have today announced their partnership to use BenevolentAI's technology to find treatments and a potential cure for the leading cause of blindness in the UK - 'age-related macular degeneration' (AMD).
Dr Laura Ferraiuolo, Lecturer in Translational Neurobiology at SITraN in Sheffield and expert in ALS (Amyotrophic Lateral Sclerosis), disease talks about the advancement of research for ALS and the need for researchers to welcome new technologies to help them progress in finding potential new cures.
Ken Mulvany talks to IBT about how the efficiency in the pharmaceutical industry can be increased by integrating AI methods.
One of the largest AI enterprises in the world, BenevolentAI has acquired a research facility in Babraham, FierceBiotech is reporting on it.
Ian Churcher talks to chemical engineering news about targeted protein degradation.
Ken Mulvany talks to CityAm about AI, innovations and his ambitions for BenevolentAI
Listen to Jackie Hunter taking part to the BBC podcast with Evan Davis to discuss the relationship between three important pillars of modern society: science, business and the consumer. Is the public right to be suspicious of business and the science it's selling? Why do some us fear GM foods, nanotechnology, AI and gene editing?
Read more about the current advancements and innovations made towards finding a cure for ALS (Lou Gehrig’s disease)
WIRED talks to Jackie Hunter about the positive disruption BenevolentAI is bringing to the pharma industry, and the scientific unknowns its helping to unlock using AI.
FierceBiotech covers the news that we have hired Dr Ian Churcher MA, DPhil as VP of Drug Discovery and Preclinical development. Ian joins from GSK where he previously headed up a Discovery Performance Unit.
BenevolentAI, one of the world’s largest private AI companies, today announced it has hired Dr Ian Churcher as its new VP of Drug Discovery & Preclinical Development of its bioscience subsidiary BenevolentBio.
Taking a closer look at how big data and machine learning is transforming precision medicine, Adi Gaskell covers our work at BenevolentAI and the partnership with Sheffield Institute for Translational Neuroscience (SITraN) for Motor Neuron Disease research.
We teamed up with Sheffield Institute for Translational Neuroscience (SITraN) to test some of our AI-driven hypotheses in its ALS disease models. Dr Laura Ferraiulo, co-lead on the project from SITraN, spoke to IDG Connect about how this led to a potentially major breakthrough.
Our founder Ken Mulvany features in an article looking at the UK’s growing performance in AI technology and the investment the country’s industry is attracting. Ken speaks to Bloomberg’s Giles Turner about BenevolentAI's hiring spree and the 50 roles we are looking to fill.
Sheffield and London, UK - 25 May 2017. The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world’s leading centres for research into Motor Neurone Disease, Alzheimer’s and Parkinson’s Disease, today announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results.
Nanalyze includes BenevolentAI in its round up of computational drug discovery start-ups using AI.
Ken Mulvany, is interviewed by Business Insider UK in an article exploring BenevolentAI’s work to develop new drugs for diseases like Alzheimer’s and ALS.
This week, Pharmaphorum covered our partnership announcement with MRC Technology. We’ve teamed up with the independent research charity to investigate new small molecule and antibody drug candidates, combining our technology and R&D experience with their expertise.
London, 11 April 2017 – BenevolentAI, a British artificial intelligence company, today announced that it has partnered with MRC Technology (“MRCT”), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
Jackie Hunter gives an interview to Labiotech around machine and healthcare and how AI could be the solution for a broken drug development process
An interview with Jackie Hunter, CEO BenevolentBio, the drug discovery arm of BenevolentAI